Core Viewpoint - Abacus Global Management, Inc. is under investigation for potential securities fraud and unlawful business practices, following allegations of manipulating financial reporting to appear more profitable than it is [1][2]. Group 1: Investigation and Allegations - An investigation is being conducted on behalf of investors of Abacus Global Management regarding possible securities fraud by the company and its officers or directors [1]. - A report by Morpheus Research claims that Abacus has altered its portfolio valuation methodology to inflate profitability and uses questionable life expectancy calculations, raising concerns about the integrity of its financial practices [2]. Group 2: Market Reaction - Following the news of the investigation and the allegations, Abacus's stock price experienced a significant decline, falling by $1.64 per share, or 21.47%, closing at $6.00 per share on June 5, 2025 [3].

Core Viewpoint - A class action securities lawsuit has been filed against DoubleVerify Holdings, Inc. alleging securities fraud affecting investors between November 10, 2023, and February 27, 2025 [1] Group 1: Allegations of the Lawsuit - The lawsuit claims that DoubleVerify's customers are shifting ad spending from open exchanges to closed platforms, limiting the company's technological capabilities and increasing competition from platforms like Meta and Amazon [2] - It is alleged that DoubleVerify's ability to monetize its Activation Services is constrained due to the high costs and time required for technology development for closed platforms [2] - The complaint states that monetization of DoubleVerify's Activation Services on certain closed platforms could take several years [2] - Competitors are reportedly better positioned to integrate AI into their offerings on closed platforms, negatively impacting DoubleVerify's competitive edge and profitability [2] - The company is accused of systematically overbilling customers for ad impressions served to declared bots from known data center server farms [2] - The risk disclosures provided by DoubleVerify are claimed to be materially false and misleading, presenting adverse facts as mere possibilities [2] - As a result of these issues, the lawsuit asserts that the positive statements made by the defendants regarding the company's business and prospects were materially false or lacked a reasonable basis [2] Group 2: Next Steps for Affected Investors - Investors who suffered losses in DoubleVerify Holdings, Inc. during the specified timeframe have until July 21, 2025, to request appointment as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4]

Core Viewpoint - A lawsuit has been filed against Centene Corporation and its senior executives for potential violations of federal securities laws, following significant discrepancies between the company's financial guidance and actual market conditions [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, titled Lunstrum v. Centene Corporation, et al., No. 25-cv-05659, with investors having until September 8, 2025, to seek lead plaintiff status [2]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Centene securities [2]. Group 2: Company Background - Centene Corporation is a healthcare company that provides services to consumers enrolled in government-sponsored healthcare programs such as Medicaid and Medicare, as well as those purchasing insurance under the Affordable Care Act [3]. Group 3: Financial Guidance and Market Conditions - On December 12, 2024, Centene announced financial guidance for fiscal year 2025, claiming stability in earnings despite challenges [4]. - The company subsequently increased its 2025 guidance on February 4, 2025, citing enrollment overperformance, and again on April 25, 2025, due to strong growth in enrollment and retention [4]. - However, the actual market conditions revealed lower than expected enrollment growth and increased morbidity rates in the majority of the states Centene serves [4]. Group 4: Stock Performance - On July 1, 2025, Centene withdrew its previous guidance after an independent actuarial report indicated that market growth in 22 of the 29 states was lower than expected, leading to a significant stock price drop of $22.87 per share, or over 40%, from $56.65 to $33.78 [5].

Core Viewpoint - A class action lawsuit has been filed against iRobot Corporation for allegedly making false and misleading statements regarding its financial stability and restructuring plan during the Class Period from January 29, 2024, to March 11, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that iRobot overstated the effectiveness of its Restructuring Plan following the termination of the Amazon Acquisition, leading to doubts about its ability to operate profitably as a standalone company [5]. - It is alleged that the defendants' public statements were materially false and misleading, which resulted in investor damages when the true information became public [5]. Group 2: Participation Information - Investors who purchased iRobot securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm for more information [3][6]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of PepGen Inc. regarding a class action lawsuit due to alleged misleading statements about the company's lead product candidate, PGN-EDO51, and its clinical study [1][3]. Summary by Relevant Sections Allegations - The complaint alleges that during the class period from March 7, 2024, to March 3, 2025, PepGen Inc. made materially false and misleading statements regarding PGN-EDO51, claiming it was more effective and safe than it actually was [3]. - It is claimed that the phase two CONNECT2 study was dangerous or deficient for FDA approval, leading to the likelihood of halting the study and overstating the product's clinical, regulatory, and commercial prospects [3]. Class Action Details - Shareholders who purchased shares during the specified class period are encouraged to register for the class action, with a deadline of August 8, 2025, to seek lead plaintiff status [4]. - Participants will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle, with no cost or obligation to participate [4]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [5].

Group 1 - Centene Corporation is under investigation for potential securities fraud and unlawful business practices involving its officers and directors [1] - On July 1, 2025, Centene withdrew its 2025 GAAP and adjusted diluted earnings per share guidance due to underperformance in market growth across 22 out of 29 states and higher-than-expected health risks affecting revenue calculations [2] - Following the announcement, Centene's stock price dropped by $22.87, or 40.37%, closing at $33.78 per share on July 2, 2025 [3] Group 2 - Pomerantz LLP is a prominent law firm specializing in corporate, securities, and antitrust class litigation, with a history of recovering significant damages for victims of securities fraud and corporate misconduct [4]

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving argenx SE and its officers or directors [1] Group 1: Regulatory Concerns - On June 30, 2025, the FDA issued an alert regarding argenx's Vyvgart Hytrulo product, indicating a potential risk of "severe worsening of chronic inflammatory demyelinating polyradiculoneuropathy" [2] - The FDA is currently evaluating the need for regulatory action based on reports received [2] Group 2: Market Reaction - Following the FDA alert, argenx's American Depositary Share (ADS) price decreased by $8.92, or 1.59%, closing at $551.22 per ADS on June 30, 2025 [2]

Core Viewpoint - Harrow, Inc. is under investigation for potential securities fraud and unlawful business practices following disappointing financial results for Q1 2025, which led to a significant drop in its stock price [1][2]. Financial Performance - Harrow reported revenue of $47.8 million for Q1 2025, which was below the consensus estimate of $57.0 million [2]. - The company also reported an adjusted EBITDA of -$1.9 million, missing the expected $11.9 million [2]. - Following the announcement of these results, Harrow's stock price decreased by $1.00 per share, or 4.07%, closing at $23.59 per share on May 8, 2025 [2]. Legal Investigation - Pomerantz LLP is investigating claims on behalf of Harrow investors regarding possible securities fraud or other unlawful business practices by the company and its officers or directors [1]. - The Pomerantz Firm has a long history in corporate and securities class litigation, having recovered significant damages for victims of securities fraud and corporate misconduct [3].

Core Viewpoint - Edelson Lechtzin LLP is investigating securities fraud claims against Hims & Hers Health, Inc. related to its partnership with Novo Nordisk, which may have misled investors regarding the nature of the collaboration and its implications for the company's stock value [1][4]. Company Overview - Hims & Hers Health, Inc. is a telehealth and online pharmacy company that provides prescription and over-the-counter medications, mental health services, and personal care products through a direct-to-consumer platform in the U.S. and the U.K. [3]. Securities Fraud Claims - The complaint alleges that Hims & Hers made materially false and misleading statements and failed to disclose critical facts about its partnership with Novo Nordisk during the class period from April 29, 2025, to June 23, 2025 [4]. - Specifically, Hims & Hers allegedly engaged in deceptive promotion and sale of Novo Nordisk's Wegovy® weight loss drug, creating a substantial risk of termination of the partnership [4]. Partnership Details - On April 29, 2025, Hims & Hers announced a long-term collaboration with Novo Nordisk, which included the immediate sale of a bundled offering of Wegovy® on its platform [5]. - However, on June 23, 2025, Novo Nordisk terminated the partnership, citing Hims & Hers' failure to comply with legal standards regarding the sale of compounded drugs and deceptive marketing practices that jeopardized patient safety [5]. Stock Impact - Following the termination announcement by Novo Nordisk, Hims & Hers' stock price dropped by $22.24 per share, representing a decline of 34.63%, closing at $41.98 per share on June 23, 2025 [5].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Harrow, Inc. and its officers or directors [1] Financial Performance - On May 8, 2025, Harrow reported first-quarter 2025 revenue of $47.8 million, which missed consensus estimates of $57.0 million [3] - The company also reported an adjusted EBITDA of -$1.9 million, falling short of the expected $11.9 million [3] - Following the financial results announcement, Harrow's stock price decreased by $1.00 per share, or 4.07%, closing at $23.59 per share on the same day [3]